Edward Licitra
- Molecular Biology
- Oncology
- Pulmonary and Respiratory Medicine top 10%
- Cancer Research top 10%
- Complementary and alternative medicine top 5%
- Co-authors
- Jun O. LiuScott W. LoweTyler JacksJennifer LanniSusan GoodinMichel B. TolédanoRobert S. DiPaolaMohamed M. Rafi
- Topics
- CAR-T cell therapy research (3 papers)Herbal Medicine Research Studies (2 papers)Lung Cancer Research Studies (2 papers)
- Journals
- New England Journal of MedicineProceedings of the National Academy of SciencesJournal of Clinical Oncology
- Partner nations
- United StatesSwitzerland
In The Last Decade
Edward Licitra
13 papers receiving 810 citations
Peers
Comparison fields: 5 of 72
- Molecular Biology 400
- Oncology 221
- Pulmonary and Respiratory Medicine 203
- Cancer Research 171
- Complementary and alternative medicine 111
Countries citing papers authored by Edward Licitra
This map shows the geographic impact of Edward Licitra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Licitra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Licitra more than expected).
Fields of papers citing papers by Edward Licitra
This network shows the impact of papers produced by Edward Licitra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Licitra. The network helps show where Edward Licitra may publish in the future.
Co-authorship network of co-authors of Edward Licitra
This figure shows the co-authorship network connecting the top 25 collaborators of Edward Licitra. A scholar is included among the top collaborators of Edward Licitra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Licitra. Edward Licitra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 2 | |
| 3 | 12 | |
| 4 | 5 | |
| 5 | 156 | |
| 6 | 26 | |
| 7 | Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. | 10 |
| 8 | 5 | |
| 9 | 4 | |
| 10 | 7 | |
| 11 | 232 | |
| 12 | 151 | |
| 13 | 225 |
About Edward Licitra
Edward Licitra is a scholar working on Oncology, Complementary and alternative medicine and Biochemistry, having authored 13 papers that have together received 838 indexed citations. Recurring topics across this work include CAR-T cell therapy research (3 papers), Herbal Medicine Research Studies (2 papers) and Lung Cancer Research Studies (2 papers). The work is most often cited by research in Complementary and alternative medicine (111 citations), Cancer Research (171 citations) and Oncology (221 citations). Edward Licitra has collaborated with scholars based in United States and Switzerland. Frequent co-authors include Jun O. Liu, Scott W. Lowe, Tyler Jacks, Jennifer Lanni, Susan Goodin, Michel B. Tolédano, Robert S. DiPaola, Mohamed M. Rafi, George H. Lambert and Robert J. Meeker. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.